Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06057714 · ClinicalTrials.gov registry record

Quantitation and Spatial Registration of Airways Dysfunction With Dynamic 19F MRI in Cystic Fibrosis

A clinical trial of Cystic Fibrosis and Ventilatory Defect, sponsored by University of North Carolina, Chapel Hill.

Recruiting
Registry status
30
Enrollment target
1
Study location

NCT06057714: Recruiting study of Cystic Fibrosis and Ventilatory Defect, sponsored by University of North Carolina, Chapel Hill.

NCT06057714 is a study of Cystic Fibrosis and Ventilatory Defect that is actively recruiting participants, run by University of North Carolina, Chapel Hill. The registered enrollment target is 30 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06057714, a study of Cystic Fibrosis and Ventilatory Defect, is actively recruiting participants, sponsored by University of North Carolina, Chapel Hill.

RECRUITING
Registry status
30 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to look at lung ventilation in people with cystic fibrosis over time (1 year) using magnetic resonance imaging (MRI) with an inhaled contrast gas, and compare these measures to lung function assessed by spirometry and multiple breath nitrogen washout. This study also looks at how these measures change in response to a pulmonary exacerbation and treatment (if applicable). Over the span of a year, participants would be asked to complete 3-5 visits to the University of North Carolina at Chapel Hill (UNC). with each lasting up to 4 hours. If participants do not have a pulmonary exacerbation during the year they would be asked to complete 3 visits (one at enrollment, a second roughly 2 weeks later, and the third approximately a year later). If participants do experience a CF pulmonary exacerbation they would complete 5 visits (Visit 1, Visit 2, two exacerbation visits with one before treatment and the other after, and Visit 3 at one year after Visit 1). Only one exacerbation per participant will be tracked. Participants are eligible for this study if they are 18 years old or older, have Cystic Fibrosis (CF) with mild lung disease (FEV1 \>/= 60%), and can undergo an MRI. There are no known benefits for participating in this study.

Primary Outcome

VDP measured at Day 1 and Day 14, expressed as a percentage of total lung volume

Interventions

  • COMBINATION_PRODUCT 19F MRI

Study Locations (1)

North Carolina

  • Univeristy of North Carolina at Chapel Hill - Chapel Hill

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2021-01-20
Est. Completion 2026-06

What NCT06057714 shows while recruiting

NCT06057714 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (83% lower).

The record links to 2 conditions, with Cystic Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which 19F MRI is the first listed.

NCT06057714 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT06057714 about?

NCT06057714 is a clinical study titled "Quantitation and Spatial Registration of Airways Dysfunction With Dynamic 19F MRI in Cystic Fibrosis". The purpose of this study is to look at lung ventilation in people with cystic fibrosis over time (1 year) using magnetic resonance imaging (MRI) with an inhaled contrast gas, and compare these measures to lung function assessed by spirometry and multiple breath nitrogen washout. This study also loo...

What is the current status of trial NCT06057714?

This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2021-01-20. Estimated completion is 2026-06.

What conditions does trial NCT06057714 study?

This clinical trial studies the following conditions: Cystic Fibrosis, Ventilatory Defect.

What interventions are being tested in trial NCT06057714?

The interventions under investigation include: 19F MRI (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT06057714?

This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06057714 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cystic Fibrosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06057714's enrollment target sits among peer trials

30 113th of 169 higher than 51 of 169 other Cystic Fibrosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cystic Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06057714, the US trial registry maintained by the National Library of Medicine. NCT06057714 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.